Likewise, early recombinant IFN-β therapy may be considered to prevent the development of hypoxemic pneumonia in patients whose auto-Abs do not neutralize IFN-β (Monk et al., 2021; Vinh et al., 2021). The gene discussed is IFNB1; the disease is pneumonia.